These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 407600)

  • 1. The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954.
    Coward DM; Doggett NS
    Psychopharmacology (Berl); 1977 Apr; 52(2):165-71. PubMed ID: 407600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent.
    Coward DM; Doggett NS; Sayers AC
    Arzneimittelforschung; 1977; 27(12):2326-32. PubMed ID: 580044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
    Horst WD; Pool WR; Spiegel HE
    Eur J Pharmacol; 1973 Mar; 21(3):337-42. PubMed ID: 4736076
    [No Abstract]   [Full Text] [Related]  

  • 4. Tremorogenesis by LON-954 [N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride]: evidence for the involvement of 5-hydroxytryptamine.
    Mohanakumar KP; Ganguly DK
    Brain Res Bull; 1989 Feb; 22(2):191-5. PubMed ID: 2706533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tremulous jaw movements in rats: a model of parkinsonian tremor.
    Salamone JD; Mayorga AJ; Trevitt JT; Cousins MS; Conlan A; Nawab A
    Prog Neurobiol; 1998 Dec; 56(6):591-611. PubMed ID: 9871939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Summarizing description of the pharmacology of budipine, a new 4,4-diphenylpiperidine derivative used in Parkinson therapy (author's transl)].
    Menge HG; Brand U
    Arzneimittelforschung; 1982; 32(2):85-98. PubMed ID: 7199925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of LON 954 tremor by typical and atypical neuroleptics--an indication of striatal dopamine antagonism.
    Coward DM; Doggett NS
    Psychopharmacology (Berl); 1980 Feb; 67(2):177-80. PubMed ID: 6102779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs for Parkinson's disease reduce tremor induced by physostigmine.
    Gothóni P; Lehtinen M; Fincke M
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Jul; 323(3):205-10. PubMed ID: 6621715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harmine-, LON-954- and 5-hydroxytryptophan-induced tremors in rats withdrawn from ethanol.
    Gothóni P
    Acta Pharmacol Toxicol (Copenh); 1985 Jul; 57(1):40-6. PubMed ID: 3876687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some initial animal and human pharmacological studies with benapryzine (BRL 1288).
    Brown DM; Hughes BO; Marsden CD; Meadows JC; Spicer B
    Br J Pharmacol; 1973 Mar; 47(3):476-86. PubMed ID: 4581246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 2-antagonistic effect of N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride (LON-954).
    Das M; Chauhan SP; Ganguly DK
    Eur J Pharmacol; 1988 Apr; 149(1-2):55-60. PubMed ID: 2899516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
    Close SP; Elliott PJ; Hayes AG; Marriott AS
    Psychopharmacology (Berl); 1990; 102(3):295-300. PubMed ID: 1979176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride (LON-954), a tremorogen, on rat diaphragm.
    Vedasiromoni JR; Ganguly DK
    Jpn J Pharmacol; 1984 Mar; 34(3):353-5. PubMed ID: 6727073
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism.
    Gomez-Mancilla B; Boucher R; Bédard PJ
    Mov Disord; 1992; 7(1):43-7. PubMed ID: 1348351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metoprolol in the treatment of neuroleptic-induced tremor: case report.
    Chaturvedi SK
    J Clin Psychiatry; 1987 Sep; 48(9):378. PubMed ID: 2887551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
    Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.